Skip to main content
. 2017 Jan 2;8(7):11906–11916. doi: 10.18632/oncotarget.14439

Table 4. Comparison of sensitivity between CEA and cfDNA LHI for CRC patients.

All stage (n = 114) Stage I/II (n = 57) Stage III/IV (n= 57)
CEA (≥5.0 ng/mL)
  Sensitivity 54.4% (62/114) 40.4% (23/57) 68.4% (39/57)
cfDNA LHI
  Sensitivity 65.8% (75/114) 63.2% (36/57) 68.4% (39/57)

Abbreviations: cfDNA, circulating cell-free DNA; LHI, LINE-1 hypomethylation index; CRC, colorectal cancer; CEA, carcinoembryonic antigen.